Abstract 2294P
Background
Although the average age of lung cancer diagnosis is 70, thousands of cases are diagnosed annually in patients under 45. Previous work has shown that lung cancers in younger patients frequently harbor targetable somatic alterations, suggesting young age may be an emerging clinical biomarker of lung cancer biology. Given young age at diagnosis and absence of known environmental insults, we hypothesized that underlying germline variation predisposes to developing lung cancer at a young age.
Methods
We assembled a cohort of 350 patients diagnosed with NSCLC/SCLC at age 45 or younger and performed germline multi-gene panel testing and whole-genome sequencing (WGS) from peripheral blood, along with tumor panel-based NGS. Germline results were compared to WGS from ancestry-matched, uniformly processed non-cancer controls as part of the 1000 Genomes Project as well as exomes from lung cancer patients diagnosed over 45 as part of The Cancer Genome Atlas (TCGA).
Results
Preliminary WGS from 243 patients shows at least 30% of patients carry clinically actionable pathogenic germline variants (PGVs) in cancer-associated genes, at rates exceeding those seen in other cancers – with gene set enrichment analyses (GSEA) showing key age-specific differences compared to lung cancer patients in TCGA. GSEA show high carrier rates of rare PGVs in several cancer-related pathways, including genes mediating DNA damage repair and receptor tyrosine kinase signaling. Common variant polygenic risk scores were negatively associated with rare PGVs, suggesting an independent contribution to risk. Clinicopathologic analysis of this cohort shows enrichment for never-smoking status (74%), female sex (59%), and adenocarcinoma (LUAD, 89%). Of LUAD, 88% harbor targetable somatic alterations: 38.9% EGFR-mutant (75% exon 19 deleted), 24.1% ALK-rearranged, and 33% fusion-positive.
Conclusions
Rare PGVs mediate lung cancer risk in young lung cancer patients, with age-specific differences compared to patients diagnosed at older ages. These results prompt consideration of a group based on germline risk that may benefit from CT screening as part of future changes to clinical care. Further work will delineate additional risk mediated by non-coding and structural variants.
Clinical trial identification
NCT05265429: Biology of Young Lung Cancer (The YOUNG LUNG Study)
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
DFCI Wong Family Award in Translational Oncology, Friends of Dana-Farber, and NIH Training Grant (T32CA009172).
Disclosure
J. Lin: Financial Interests, Personal, Other, Consulting: Turning Point Therapeutics; Financial Interests, Personal, Advisory Board, Consulting: Blueprint Medicines; Financial Interests, Personal, Other, Consulting: Nuvalent; Financial Interests, Personal, Other, Consulting: Elevation Oncology; Financial Interests, Personal, Other, Honorarium, travel: Pfizer; Financial Interests, Personal, Advisory Board, Consulting: Genentech; Financial Interests, Personal, Other, Consulting: C4 Therapeutics; Financial Interests, Personal, Other, Consulting: Bayer; Financial Interests, Personal, Other, Consulting: Novartis; Financial Interests, Personal, Other, Consulting: Mirati Therapeutics; Financial Interests, Personal, Other, Consulting: Regeneron; Financial Interests, Personal, Other, Consulting: CLaiM Therapeutics; Financial Interests, Institutional, Local PI: Turning Point Therapeutics; Financial Interests, Institutional, Local PI: Neon Therapeutics; Financial Interests, Institutional, Local PI: Relay Therapeutics; Financial Interests, Institutional, Local PI: Bayer; Financial Interests, Institutional, Local PI: Elevation Oncology; Financial InterJ.E. Garber: Financial Interests, Personal, Advisory Board: Helix, Konica-Minolta, American Association for Cancer Research, The James P. Wilmot Foundation, Inc., Earli Inc.; Financial Interests, Personal, Full or part-time Employment: Breast Cancer Research Foundation. P.A. Jänne: Financial Interests, Personal, Advisory Board, Consulting fees for advice on drug development: AstraZeneca, Boehringer Ingelheim, Pfizer, Roche/Genentech, Chugai Pharmaceuticals, Eli Lilly, Voronoi, Daiichi Sankyo, Novartis, Sanofi, Takeda Oncology, Mirati Therapeutics, Trasncenta, Silicon Therapeutics, Syndax, Nuvalent, Bayer, Eisai, Allorion Therapeutics, Accutar Biotech, AbbVie, Duality Biologics; Financial Interests, Personal, Advisory Board, Consulting fees for advice on diagnostic development: Biocartis; Financial Interests, Personal, Advisory Board, Consulting fee for advice on drug development: Merus, Frontier Medicines; Financial Interests, Personal, Advisory Board, Consulting fees for advice on drug development: Hongyun Biotechnology; Financial Interests, Personal, Stocks/Shares: Gatekeeper Pharmaceuticals, Allorion Therapeutics; Financial Interests, Personal, Royalties, I receive post-marketing royalties from being an inventor on a DFCI owned patent on EGFR mutations licensed to Lab Corp: Lab Corp; Financial Interests, Institutional, Research Grant, Sponsored research agreement with my institution: AstraZeneca, Daiichi Sankyo, Puma, Eli Lilly, Boehringer Ingelheim, Revolution Medicines, Takeda Oncology. All other authors have declared no conflicts of interest.
Resources from the same session
2273P - Influence of body mass index (BMI) on the response to chemotherapy in patients with HER2+ breast cancer: Role of the leptin axis
Presenter: Marta González Rodríguez
Session: Poster session 08
2274P - Deep learning-based prediction of pathologic complete response to neoadjuvant therapy in breast cancer using H&E images and RNA-Seq in the IMMUcan study
Presenter: Christian Esposito
Session: Poster session 08
2275P - Circulating leptin and adiponectin levels in premenopausal women with and without breast cancer (BC) and a body mass index (BMI) ≥25 kg/m2
Presenter: Isabel Calvo
Session: Poster session 08
2276P - Regulation of major histocompatibility class-I gene methylation using DNA methyltransferase inhibitor and PD-L1 inhibitor in triple-negative breast cancer
Presenter: Young Ju Jeong
Session: Poster session 08
2277P - A colorimetric biosensor to track Trop-2 status of tumor cells for diagnosis of breast cancer
Presenter: Tianyu Zeng
Session: Poster session 08
2278P - Endothelial cell heterogeneity defined by single-cell spatial transcriptomic analysis of breast cancers
Presenter: Krisztian Homicsko
Session: Poster session 08
2279P - Glucocorticoid receptor antagonism and beta adrenergic receptor inhibition: Implications in triple-negative breast cancer brain metastasis
Presenter: Andra Antohi
Session: Poster session 08
2280P - MiR-193a-3p: A pan-repressor of H2S synthesizing enzymes regulates tumorigenesis and immunosurveillance in breast cancer
Presenter: Alyaa Dawoud
Session: Poster session 08
2281P - Multi-omics evaluation of TFE3-fusions and potential association with immuno-metabolic vulnerabilities in alveolar soft part sarcoma (ASPS) and translocation-positive renal cell carcinoma (tRCC)
Presenter: Shuanzeng Wei
Session: Poster session 08
2282P - Tissue glycan profiling in predicting immunotherapy response in renal cell carcinoma and hepatocelllular carcinoma
Presenter: Qin Jian Low
Session: Poster session 08